HOLD - Do not add on weakness, do not trim on strength until Q3 print resolves margin trajectory; tighten stop loss to $60.50-$60.80 range

• Gross margin compression from 28.2% to 27.8% represents second consecutive quarter of margin drift, not cyclical noise—pricing lever hitting elasticity walls
• Technical distribution signals: MACD crossed below signal line, histogram negative for two consecutive sessions after peaking at 0.85 on August 24th, failed upper Bollinger Band test with lighter volume on push to $64.70, price under 10 EMA
• Leverage risk in higher-for-longer environment: $21.6 billion debt with refinancing costs rising from $137 million in Q1 2025 to $148 million in Q1 2026; 88% free cash flow dividend coverage is tight
• GLP-1 drugs represent a structural demand headwind for the snacking category that neither the aggressive analyst nor trader addressed
• Valuation stretched after 19.6% YTD gain: forward PE 18.7 versus trailing PE 23.08, paying for 23% forward earnings growth that must materialize
• CEO insider sale (10b5-1 plan) at current prices is a yellow flag on management's near-term valuation view
• Q4 free cash flow of $2 billion cannot cover quarterly dividends—dividends are paid from the current quarter, not accumulated
• Three correlated risks compounding: rate path/refinancing risk, FX translation risk on EM-heavy revenue mix, and cocoa cycle risk on top of elevated leverage

→ vs aggressive: Dismissed 40 basis point gross margin compression as 'wobble'—actually the beginning of a pattern with pricing power hitting elasticity walls, and commodity hedges will roll off without guarantee of lower input costs

→ vs aggressive: Characterized failed upper Bollinger test as 'textbook retest'—ignores MACD momentum deterioration, histogram flipping negative, lighter volume on the $64.70 push versus July breakout, and price slipping under 10 EMA

→ vs aggressive: Waved off leverage risk by citing Q4 free cash flow of $2 billion—but you cannot pay quarterly dividends from Q4 cash; 88% dividend coverage is tight by any definition

→ vs aggressive: Framed this as 'asymmetric upside'—actually asymmetric exposure to being wrong given three correlated risks on top of already-rallied name

HOLD with three refinements: (1) Move stop loss from 61.29 to 60.50–60.80, (2) Replace rigid no-add-no-trim rule with contingent framework based on defined price action triggers, (3) Acknowledge price action between now and Q3 provides actionable information

• Two consecutive quarters of 40 basis point margin compression is a pattern, not noise, but not catastrophic
• Hedge book exposure risk if cocoa stays elevated 18-24 months as West African supply issues persist
• MACD crossed below signal, histogram flipped negative, price slipped under 10 EMA, volume on push to 64.70 was lighter than July breakout — momentum decay, not coiled spring
• Downside risk if Q3 confirms margin deterioration is 8–12%, not 5%, given leverage, rate path, and GLP-1 overhang
• Management raised full-year organic growth guidance — a signal being discounted by conservative analyst
• Q4 generates $2 billion in free cash flow; negative working capital model is a structural cash flow advantage
• FCF coverage is tight at 88% on TTM basis
• GLP-1 overhang is priced in gradually and is a long-term concern, not a Q3 catalyst or thesis-breaker
• CEO 10b5-1 sale was mechanical (adopted May), CEO still holds over 85 million shares directly — not a meaningful signal
• Peer reads from Hershey and KHC confirm MDLZ faces category-wide cocoa cost environment, not an idiosyncratic problem
• Polymarket recession probability at 8% supports defensive positioning
• September Fed cut probability at 1%; rates are sticky but not likely to move materially against the position
• PCE picking up is a headwind to multiples but not an acute crisis
• Current stop at 61.29 (50 SMA) is a guaranteed stop-hunt scenario; needs breathing room below 50 SMA
• If stock closes above 64.77 on rising volume with MACD re-crossing above signal, a modest add is justified
• If stock closes below 61.29 on volume with MACD continuing to roll, that is a trim signal
• HOLD is the floor, not the ceiling — but ceiling is not achievable right now
• Adding ahead of Q3 is poor risk management, but paralysis at every technical level is also wrong

→ vs aggressive: Risk-reward of 3-to-1 from 50 SMA is overstated — downside is 8–12%, not 5%, if Q3 confirms margin deterioration

→ vs aggressive: Two consecutive quarters of 40 bps margin compression is a pattern, not noise — cannot dismiss after two quarters what was called a pattern after one

→ vs aggressive: Hedge book works in normal times but roll-off exposure if cocoa stays elevated 18–24 months from West African supply issues

→ vs aggressive: Failed upper Bollinger Band test is genuinely concerning — MACD crossed below signal, histogram flipped negative, price under 10 EMA, lighter volume on push to 64.70; this is momentum decay, not coiled spring

→ vs aggressive: Reddit silence is not a bullish signal — constructing positive signal from absent data is a cognitive trap

→ vs conservative: Two consecutive 40 bps quarters is not a confirmed deterioration pattern — equally a stretch as calling one quarter a pattern

→ vs conservative: Management guide raise for full-year organic growth is a signal being discounted — management has visibility into hedge book, pricing, and volume trajectory

→ vs conservative: Leverage argument is technically correct but practically overstated; Q4 generates $2B FCF and negative working capital model provides structural cash flow advantage not captured in static ratios

→ vs conservative: GLP-1 overhang is priced in gradually over a year, a long-term concern not warranting exclusion from any branded food company, and certainly not a Q3 catalyst

→ vs conservative: CEO insider sale is weakest argument — 10b5-1 plan adopted in May, sale was mechanical, CEO still holds 85M+ shares directly; reading this as near-term valuation signal is confirmation bias

→ vs conservative: Stop at 60.50 is too aggressive given long-term uptrend — creates whipsaw risk on normal 50 SMA retest and chops out position right before catalyst resolves